2015 Fiscal Year Final Research Report
The development of new angiotensin II receptor vaccine
| Project/Area Number |
25870715
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Kidney internal medicine
Immunology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 高血圧 / アンジオテンシン / ワクチン / 粘膜免疫 |
|---|
| Outline of Final Research Achievements |
To develop the new treatment for hypertension, that improves medical adherence, I focused on the vaccine strategy. To avoid the injection-related pain and skin adverse events, I aimed to create a new non-injectable anti-hypertensive vaccine.
For the development of oral anti-hypertensive vaccine, the expression vector which angiotensin II type 1 receptor (AT1) - Cholera toxin B subunit(CTB) chimeric sequence was inserted into was used to transformed the rice. Although resultant transgenic rice seeds expressed AT1-CTB protein, its immunogenicity to AT1 was poor.
For the development of nasal vaccine, AT1 partial peptide was synthesized and conjugated with pneumococcal surface protein A (PspA). AT1-PspA antigen was mixed with adjuvant and incorprated into nanogels. Intranasal immunization with AT1-PspA vaccine induced AT1-specific serum IgG antibody and also lower blood pressure in the spountaneously hypertensive rats.
|
| Free Research Field |
高血圧
|
